Novartis to acquire IBT portfolio company Avidity

Summary by AI BETAClose X

International Biotechnology Trust PLC (IBT) announced that Avidity Biosciences, an IBT portfolio company, will be acquired by Novartis for $12 billion in cash. Avidity shareholders will receive $72.00 per share, a 46% premium over the closing share price on October 24th. As of October 23rd, Avidity represented 2.55% of IBT's Net Asset Value and was the eighth-largest holding in IBT's quoted portfolio. This acquisition marks IBT's ninth M&A transaction involving a portfolio holding this year and the 34th since 2020. The updated valuation of IBT's holding in Avidity will be included in IBT's NAV as at close of business today, to be reported tomorrow, October 28.

Disclaimer*

UK 100

Latest directors dealings